Design, synthesis and bioactivity of indobufen derivatives
Abstract
screening workflow. Early inflammatory profiling in fibroblast-like synoviocytes (FLS) identified compound A1 as a lead candidate with pronounced suppression of pro-inflammatory mediators and matrix-degrading enzymes. In a RANKL-induced RAW264.7 osteoclastogenesis model, A1 inhibited osteoclast maturation at non-cytotoxic concentrations, markedly reducing the expression of osteoclast functional proteins (MMP9 and cathepsin K) and disrupting F-actin ring formation and multinucleation. Collectively, these findings demonstrate that indobufen scaffold modification can yield small molecules with dual anti-inflammatory and anti-osteoclastogenic activities and highlight A1 as a promising lead compound for the development of therapeutics targeting osteoporosis and inflammation-associated bone loss.
Fields of Study & Subjects
Bone Metabolism and Diseases
NF-κB Signaling Pathways
Signaling Pathways in Disease
Publication details
- Journal / source
- RSC Advances
- Publisher
- Royal Society of Chemistry (RSC)
- Volume
- 16
- Issue
- 24
- Pages
- 21510–21518
- Publication date
- 1 January 2026
- Language
- EN